Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Venus Remedies Ltd

VENUSREM

Venus Remedies Ltd

VENUSREM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹464 cr, stock is ranked 1,856
High RiskStock is 4.03x as volatile as Nifty
344.500.85% (-2.95)
344.500.85% (-2.95)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹464 cr, stock is ranked 1,856
High RiskStock is 4.03x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹464 cr, stock is ranked 1,856
High RiskStock is 4.03x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
16.280.95—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.936.390.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.33%, vs industry avg of 9.21%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.14% to 0.16%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue420.28402.31374.66327.98375.99600.36608.49565.83613.03625.82
Raw Materialssubtract242.04223.58204.84189.67168.45347.94383.50322.95357.35554.40
Power & Fuel Costsubtract4.014.144.294.864.734.584.715.526.35
Employee Costsubtract32.4434.2739.3142.1046.0246.0252.3357.0566.95
Selling & Administrative Expensessubtract57.5678.3079.4154.5267.1595.9985.5492.49100.77
Operating & Other expensessubtract1.069.035.097.1752.338.9811.9817.4710.43
Depreciation/Amortizationsubtract41.6840.2633.8333.9832.0135.2833.5332.3026.4424.87
Interest & Other Itemssubtract37.9834.3735.4325.4113.3413.020.480.120.090.12
Taxes & Other Itemssubtract1.81-4.563.16-1.151.96-13.21-4.3211.3616.1517.91
EPS1.49-14.36-24.87-23.16-8.1050.0431.6919.8821.3221.34
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Venus Remedies Ltd16.300.95—
Sun Pharmaceutical Industries Ltd45.086.430.75%
Cipla Ltd31.714.880.80%
Torrent Pharmaceuticals Ltd70.1816.950.82%

Price Comparison

Compare VENUSREM with any stock or ETF
Compare VENUSREM with any stock or ETF
VENUSREM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding41.76%0.00%0.15%1.06%57.03%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun1.00%0.98%1.03%1.59%1.48%1.06%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

VENUSREM has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2013

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 23, 2013

Cash Dividend

Ex DateEx DateSep 20, 2012

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 20, 2012

Cash Dividend

Ex DateEx DateSep 22, 2011

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 22, 2011

Cash Dividend

Ex DateEx DateSep 23, 2010

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 23, 2010

News & Opinions
Corporate
Venus Remedies AGM scheduled

Venus Remedies announced that the 35th Annual General Meeting (AGM) of the company will be held on 23 September 2024.Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 3.39% in the June 2024 quarter

Net profit of Venus Remedies rose 3.39% to Rs 1.22 crore in the quarter ended June 2024 as against Rs 1.18 crore during the previous quarter ended June 2023. Sales rose 14.15% to Rs 108.61 crore in the quarter ended June 2024 as against Rs 95.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales108.6195.15 14 OPM %10.3710.93 - PBDT12.8312.60 2 PBT6.855.05 36 NP1.221.18 3 Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Venus Remedies to discuss results

Venus Remedies will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Venus Remedies postpones board meeting

Venus Remedies has postponed the meeting of the Board of Directors which was scheduled to be held on 20 July 2024. The meeting will now be held on a later date.Powered by Capital Market - Live

1 month agoCapital Market - Live

Venus Remedies edges higher after bagging supply order for oncology drugs from PAHO

2 months agoBusiness Standard

Venus Remedies up 8% on order win from UNICEF for bacterial infection drug

2 months agoBusiness Standard

Venus Remedies soars after bagging Ceftriaxone supply contract from UNICEF

2 months agoBusiness Standard

Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines

10 months agoMoneycontrol

Venus Remedies trades 2% up on approval to market cancer drugs in Serbia

11 months agoMoneycontrol

Venus Remedies launches flagship R&D drug Elores in Oman

1 year agoEconomic Times